Publication NumberUS 20160208011
Assignees
  • The Board of Trustees of the Leland Stanford Junior University
  • The United States Government as represented by the Department of Veterans Affairs
StatusPatent Application
Application Number14/991813
AvailabilityUnknown
Filing Date2016-01-08
Publication Date2016-07-21

Abstract

Methods of treating an adult mammal for an aging-associated impairment are provided. Aspects of the methods include modulating CCR3, e.g., by modulating eotaxin-1/CCR3 interaction, in the mammal in a manner sufficient to treat the mammal for the aging-associated impairment. A variety of aging-associated impairments may be treated by practice of the methods, which impairments include cognitive impairments.

Claims

  • 1. A method of treating an adult mammal for an aging-associated impairment, the method comprising: modulating CCR3 in the mammal in a manner sufficient to treat the adult mammal for the aging-associated impairment.
  • 2. The method according to claim 1, wherein modulating CCR3 comprising modulating eotaxin-1/CCR3 interaction.
  • 3. The method according to claim 2, wherein eotaxin-1/CCR3 interaction is modulated by reducing active systemic eotaxin-1 in the mammal.
  • 4. The method according to claim 3, wherein the active systemic eotaxin-1 is reduced in the mammal by administering to the mammal an effective amount of an active systemic eotaxin-1 reducing agent.
  • 5. The method according to claim 4, wherein the active systemic eotaxin-1 reducing agent is an eotaxin-1 binding agent.
  • 6. The method according to claim 5, wherein the eotaxin-1 binding agent comprises an antibody or binding fragment thereof.
  • 7. The method according to claim 5, wherein the eotaxin-1 binding agent comprises a small molecule.
  • 8. The method according to claim 4, wherein the active systemic eotaxin-1 reducing agent comprises an eotaxin-1 expression inhibitory agent.
  • 9. The method according to claim 8, wherein the eotaxin-1 expression inhibitory agent comprises a nucleic acid.
  • 10. The method according to claim 1, wherein eotaxin-1/CCR3 interaction is modulated by reducing CCR3 activity in the mammal.
  • 11. The method according to claim 10, wherein the CCR3 activity is reduced in the mammal by administering to the mammal an effective amount of an active CCR3 reducing agent.
  • 12. The method according to claim 11, wherein the active CCR3 reducing agent is a CCR3 binding agent.
  • 13. The method according to claim 12, wherein the CCR3 binding agent comprises an antibody or binding fragment thereof.
  • 14. The method according to claim 12, wherein the CCR3 binding agent comprises a small molecule.
  • 15. The method according to claim 11, wherein the active CCR3 reducing agent comprises a CCR3 expression inhibitory agent.
  • 16. The method according to claim 15, wherein the CCR3 expression inhibitory agent comprises a nucleic acid.
  • 17. The method according to claim 1, wherein the mammal is a primate.
  • 18. The method according to claim 17, wherein the primate is a human.
  • 19. The method according to claim 1, wherein the adult mammal is an elderly mammal.
  • 20. The method according to claim 19, wherein the elderly mammal is a human that is 60 years or older.
  • 21. The method according to claim 1, wherein the aging-associated impairment comprises a cognitive impairment.
  • 22. The method according to claim 1, wherein the adult mammal suffers from an aging associated disease condition.
  • 23. The method according to claim 1, wherein the aging associated disease condition is a cognitive decline disease condition.